

IN THE CLAIMS

Please amend the claims as follows.

- 1-9. (Canceled)
- ~~2~~ ~~10~~. (Previously presented) A vector comprising the nucleic acid of claim ~~11~~¹.
- ~~3~~ ~~11~~. (Previously presented) The vector of claim ~~10~~², wherein said vector is an expression vector.
- ~~4~~ ~~12~~. (Previously presented) The vector of claim ~~10~~² that is a prokaryotic vector.
- ~~5~~ ~~13~~. (Previously presented) The vector of claim ~~10~~² that is a eukaryotic vector.
- ~~6~~ ~~14~~. (Previously presented) A host cell comprising the vector of claim ~~10~~².
- ~~7~~ ~~15~~. (Previously presented) A host cell of claim ~~14~~⁶ that is a prokaryotic cell.
- ~~8~~ ~~16~~. (Previously presented) A host cell of claim ~~14~~⁶ that is a eukaryotic cell.
- 17-40. (Canceled)
- ~~1~~ ~~17~~. (Previously Presented) An isolated nucleic acid comprising a nucleotide sequence selected from the group consisting of:
- (a) a nucleotide sequence as set forth in SEQ ID NO: 2;
 - (b) a nucleotide sequence encoding the polypeptide as set forth in SEQ ID NO: 7;
 - (c) a nucleotide sequence complementary to (a) or (b).

42-47. (Canceled)

9 ~~48~~. (Previously presented) A process of producing a peripheral-type benzodiazepine-associated protein (PAP) comprising culturing the host cell of either claim ~~13~~⁷ or ~~18~~⁸ under suitable conditions to express a peripheral-type benzodiazepine-associated protein-7 (PAP7) encoded by the nucleic acid.

10 ~~48~~⁹. (Previously presented) The process of claim ~~48~~⁹, wherein the vector further comprises a heterologous promoter operatively linked to the nucleotide sequence encoding the peripheral-type benzodiazepine-associated protein-7 (PAP7) polypeptide.

11 ~~50~~. (Previously presented) A reagent comprising a nucleic acid of claim ~~41~~¹, wherein the nucleic acid is detectably labeled.

12 ~~51~~. (Previously presented) A reagent comprising a single-stranded nucleic acid of claim ~~41~~¹, wherein the nucleic acid is complementary and is detectably labeled.

13 ~~52~~. (Previously presented) A reagent comprising a single-stranded nucleic acid of claim ~~41~~¹, wherein the nucleic acid amplifies peripheral-type benzodiazepine-receptor-associated protein-7 (PAP7) sequences.

53-82. (Canceled)